title: Treatment targets in intracerebral hemorrhage.
abstract: Intracerebral hemorrhage (ICH) imparts a higher mortality and morbidity than ischemic stroke. The therapeutic interventions that are currently available focus mainly on supportive care and secondary prevention. There is a paucity of evidence to support any one acute intervention that improves functional outcome. This chapter highlights current treatment targets for ICH based on the pathophysiology of the disease.
authors: Department of Neurology, University of Texas Medical School-UT Health, 6431 Fannin, MSB 7.118, Houston, TX 77030, USA.
authors: Navdeep
authors: N
authors: Sangha
authors: Nicole R
authors: NR
authors: Gonzales
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology; D001929:Brain Edema / Q000188:drug therapy / Q000209:etiology; D000068579:Celecoxib; D016657:Cerebral Amyloid Angiopathy / Q000150:complications / Q000188:drug therapy; D002543:Cerebral Hemorrhage / Q000209:etiology / Q000235:genetics / Q000628:therapy*; D002986:Clinical Trials as Topic; D024141:Collagen Type IV / Q000235:genetics; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D015942:Factor VIIa / Q000627:therapeutic use; D006406:Hematoma / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D011720:Pyrazoles / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; C547475:COL4A1 protein, human; D024141:Collagen Type IV; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D011994:Recombinant Proteins; D013449:Sulfonamides; C103587:recombinant FVIIa; D015942:Factor VIIa; D000068579:Celecoxib